Preclinical discovery research of E7820, a novel angiogenesis inhibitor inducing tumor vascular normalization

被引：0
|
作者：
Semba, Taro [1 ]
Funahashi, Yasuhiro [1 ,2 ]
机构：
[1] Eisai Co, Oncol PCU, Tsukuba, Ibaraki 3002635, Japan
[2] Eisai Co, BPM CFU, Andover, MA 01810 USA
来源：
JOURNAL OF PHARMACOLOGICAL SCIENCES | 2011年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：26P / 26P
页数：1
相关论文
共 25 条
  • [1] DCE-MRI as a tool to detect tumor vascular normalization by E7820, a novel angiogenesis inhibitor
    Funahashi, Yasuhiro
    Semba, Taro
    Uenaka, Toshimitsu
    Tizon, Xavier
    Serin, Guillaume
    Bichat, Francis
    Sourzat, Benedicte
    [J]. CANCER RESEARCH, 2009, 69
  • [2] Biomarker research of a novel angiogenesis inhibitor E7820 regulating integrin α2 expression
    Semba, Taro
    Funahashi, Yasuhiro
    [J]. JOURNAL OF PHARMACOLOGICAL SCIENCES, 2012, 118 : 36P - 36P
  • [3] Population pharmacokinetics of the angiogenesis inhibitor E7820 in patients with solid tumour or lymphoma
    Keizer, R. J.
    Zamacona, M. K.
    Jansen, M.
    Wanders, J.
    Beijnen, J. H.
    Schellens, J. H. M.
    Huitema, A. D. R.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 66 (05) : 736 - 737
  • [4] Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin α2 subunit on endothelium
    Funahashi, Y
    Sugi, NH
    Semba, T
    Yamamoto, Y
    Hamaoka, S
    Tsukahara-Tamai, N
    Ozawa, Y
    Tsuruoka, A
    Nara, K
    Takahashi, K
    Okabe, T
    Kamata, J
    Owa, T
    Ueda, N
    Haneda, T
    Yonaga, M
    Yoshimatsu, K
    Wakabayashi, T
    [J]. CANCER RESEARCH, 2002, 62 (21) : 6116 - 6123
  • [5] Evaluation of α2-Integrin Expression as a Biomarker for Tumor Growth Inhibition for the Investigational Integrin Inhibitor E7820 in Preclinical and Clinical Studies
    Ron J. Keizer
    Y. Funahashi
    T. Semba
    J. Wanders
    J. H. Beijnen
    J. H. M. Schellens
    A. D. R. Huitema
    [J]. The AAPS Journal, 2011, 13 : 230 - 239
  • [6] Evaluation of α2-Integrin Expression as a Biomarker for Tumor Growth Inhibition for the Investigational Integrin Inhibitor E7820 in Preclinical and Clinical Studies
    Keizer, Ron J.
    Funahashi, Y.
    Semba, T.
    Wanders, J.
    Beijnen, J. H.
    Schellens, J. H. M.
    Huitema, A. D. R.
    [J]. AAPS JOURNAL, 2011, 13 (02): : 230 - 239
  • [7] An angiogenesis inhibitor E7820 shows broad-spectrum tumor growth inhibition in a xenograft model:: Possible value of integrin α2 on platelets as a biological marker
    Semba, T
    Funahashi, Y
    Ono, N
    Yamamoto, Y
    Sugi, NH
    Asada, M
    Yoshimatsu, K
    Wakabayashi, T
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (04) : 1430 - 1438
  • [8] Preclinical discovery research of E7080, an inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) family of tyrosine kinases
    Funahashi, Yasuhiro
    [J]. JOURNAL OF PHARMACOLOGICAL SCIENCES, 2010, 112 : 33P - 33P
  • [9] The effect of AMG 706, a novel multi-kinase inhibitor, on angiogenesis and tumor growth in preclinical models
    Coxon, Angela
    Starnes, Charlie
    Bready, Jim
    Estrada, Juan
    Kaufman, Stephen
    Tasker, Andrew
    Patel, Vinod
    Kendall, Rick
    Radinsky, Robert
    Polverino, Tony
    [J]. CANCER RESEARCH, 2006, 66 (08)
  • [10] Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models
    Wu, Xiao Yu
    Xu, Hao
    Wu, Zhen Feng
    Chen, Che
    Liu, Jia Yun
    Wu, Guan Nan
    Yao, Xue Quan
    Liu, Fu Kun
    Li, Gang
    Shen, Liang
    [J]. ONCOTARGET, 2015, 6 (42) : 44563 - 44578
123